Proteinase-activated receptor 2 (PAR2) in cholangiocarcinoma (CCA) cells: Effects on signaling and cellular level

Histochemistry and Cell Biology

Volumn 138, Issue 6, 2012, Pages 913-924

  Kaufmann, Roland ^a   Hascher, Alexander ^a   Mubbach, Franziska ^a   Henklein, Petra ^b   Katenkamp, Kathrin ^a   Westermann, Martin ^a   Settmacher, Utz ^c  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c Visceral and Vascular Surgery ^*  (Germany)

Author keywords

Cell migration; Cholangiocarcinoma; Met receptor tyrosine kinase; P42 p44 MAPKinases; PAR2; Proteinase activated receptor 2; Stat3

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ALPHA [AMINO(4 AMINOPHENYLTHIO)METHYLENE] 2 (TRIFLUOROMETHYL)PHENYLACETONITRILE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEINASE ACTIVATED RECEPTOR 2; SCATTER FACTOR RECEPTOR; STAT3 PROTEIN; TRYPSIN;

ARTICLE; BILE DUCT CARCINOMA; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMINOACETONITRILE; CELL MOVEMENT; CHOLANGIOCARCINOMA; CYCLIC S-OXIDES; FLAVONOIDS; HUMANS; INDOLES; PEPTIDES; PIPERAZINES; RECEPTOR, PAR-2; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONES; TUMOR CELLS, CULTURED;

EID: 84872177768     PISSN: 09486143     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/s00418-012-1006-4     Document Type: Article

References (49)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925 (Pubitemid 37493640)
2. Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ (2009) Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 50:1861-1870
3. Boccaccio C, Ando M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio PM (1998) Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391:285-288 (Pubitemid 28099015)
4. Coelho A, Ossovskaya V, Bunnett N (2003) Proteinase-activated receptor-2: Physiological and pathophysiological roles. Curr Med Chem Cardiovasc Hematol Agents 1:61-72
5. Condeelis J, Segall JE (2003) Intravital imaging of cell movement in tumours. Nat Rev Cancer 3:921-930 (Pubitemid 37500177)
6. Darmoul D, Gratio V, Devaud H, Laburthe M (2004) Proteaseactivated receptor 2 in colon cancer: Trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 279:20927-20934 (Pubitemid 38656491)
7. Farrow B, Albo D, Berger DH (2008) The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res 149:319-328
8. Ge L, Shenoy S, Lefkowitz R, DeFea K (2004) Constitutive proteaseactivated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and-2. J Biol Chem 279:55419-55424 (Pubitemid 40066542)
9. Gee K, Brown K, Chen W, Bishop-Stewart J, Gray D, Johnson I (2000) Chemical and physiological characterization of fluo-4 Ca(2?)-indicator dyes. Cell Calcium 27:97-106 (Pubitemid 30150798)
10. Gherardi E, Birchmeier W, Birchmeier C, Woude GV (2012) Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 12:89-103
11. Grab D, Garcia-Garcia J, Nikolskaia O, Kim Y, Brown A, Pardo C, Zhang Y, Becker K, Wilson B, de Lima A, Scharfstein J, Dumler J (2009) Protease activated receptor signaling is required for African trypanosome traversal of human brain microvascular endothelial cells. PLoS Negl Trop Dis 3:e479
12. Grynkiewicz G, Poenie M, Tsien R (1985) A new generation of Ca2 + indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450 (Pubitemid 15114340)
13. Hjortoe G, Petersen L, Albrektsen T, Sorensen B, Norby P, Mandal S, Pendurthi U, Rao L (2004) Tissue factor-factor VIIa-specific upregulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 103:3029-3037 (Pubitemid 38451676)
14. Hollenberg M, Renaux B, Hyun E, Houle S, Vergnolle N, Saifeddine M, Ramachandran R (2008) Derivatized 2-furoyl-LIGRLOamide, a versatile and selective probe for proteinase-activated receptor 2: Binding and visualization. J Pharmacol Exp Ther 326:453-462
15. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, Gores GJ (2007) Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 132:384-396 (Pubitemid 46108750)
16. Jikuhara A, Yoshii M, Iwagaki H, Mori S, Nishibori M, Tanaka N (2003) MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. Life Sci 73:2817-2829 (Pubitemid 37153356)
17. Kaufmann R, Schafberg H, Nowak G (1998) Proteinase-activated receptor-2-mediated signaling and inhibition of DNA synthesis in human pancreatic cancer cells. Int J Pancreatol 24:97-102 (Pubitemid 28516518)
18. Kaufmann R, Junker B, Junker K, Nuske K, Ranke C, Zieger M, Scheele J (2002) The serine proteinase thrombin promotes migration of human renal carcinoma cells by a PKA-dependent mechanism. Cancer Lett 180:183-190 (Pubitemid 34327372)
19. Kaufmann R, Oettel C, Horn A, Halbhuber K, Eitner A, Krieg R, Katenkamp K, Henklein P, Westermann M, Bohmer F, Ramachandran R, Saifeddine M, Hollenberg M, Settmacher U (2009) Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis 30:1487-1496
20. Kawabata A, Nishikawa H, Kuroda R, Kawai K, Hollenberg M (2000) Proteinase-activated receptor-2 (PAR-2): Regulation ofsalivary and pancreatic exocrine secretion in vivo in rats and mice. Br J Pharmacol 129:1808-1814 (Pubitemid 30219027)
21. Le Clainche C, Carlier M (2008) Regulation of actin assembly associated with protrusion and adhesion in cell migration. Physiol Rev 88(2):489-513 (Pubitemid 351520086)
22. Leelawat K, Leelawat S, Tepaksorn P, Rattanasinganchan P, Leungchaweng A, Tohtong R, Sobhon P (2006) Involvement of c-Met/hepatocyte growth factor pathway in cholangiocarcinoma cell invasion and its therapeutic inhibition with small interfering RNA specific for c-Met. J Surg Res 136:78-84 (Pubitemid 44634563)
23. Magnus N, Garnier D, Rak J (2010) Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood 116:815-818
24. McGuire J, Saifeddine M, Triggle C, Sun K, Hollenberg M (2004) 2-Furoyl-LIGRLO-amide: A potent and selective proteinaseactivated receptor 2 agonist. J Pharmacol Exp Ther 309:1124-1131 (Pubitemid 38669700)
25. McSherry EA, Donatello S, Hopkins AM, McDonnell S (2007) Molecular basis of invasion in breast cancer. Cell Mol Life Sci 64:3201-3218
26. Menakongka A, Suthiphongchai T (2010) Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol 16:713-722
27. Molino M, Woolkalis MJ, Reavey-Cantwell J, Praticó D, Andrade-Gordon P, Barnathan ES, Brass LF (1997) Endothelial cell thrombin receptors and PAR-2. Two protease-activated receptors located in a single cellular environment. J Biol Chem 272: 11133-11141 (Pubitemid 27184106)
28. Morris D, Ding Y, Ricks T, Gullapalli A, Wolfe B, Trejo J (2006) Protease-activated receptor-2 is essential for factor VIIa and Xainduced signaling, migration, and invasion of breast cancer cells. Cancer Res 66:307-314 (Pubitemid 43166037)
29. Nakanuma S, Tajima H, Okamoto K, Hayashi H, Nakagawara H, Onishi I, Takamura H, Kitagawa H, Fushida S, Tani T, Fujimura T, Kayahara M, Ohta T, Wakayama T, Iseki S, Harada S (2010) Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2. Int J Oncol 36(4):793-800
30. Nickel TJ, Kabir MH, Talreja J, Stechschulte DJ, Dileepan KN (2006) Constitutive expression of functionally active protease-activated receptors 1 and 2 in human conjunctival epithelial cells. Mediators Inflamm 2006:61359
31. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J (1994) Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 91:9208-9212 (Pubitemid 24297883)
32. Okamoto W, Okamoto I, Arao T, Yanagihara K, Nishio K, Nakagawa K (2011) Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells. Br J Cancer 105:407-412
33. Ossovskaya V, Bunnett N (2004) Protease-activated receptors: Contribution to physiology and disease. Physiol Rev 84:579-621 (Pubitemid 38365493)
34. Peruzzi B, Bottaro DP (2006) Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12:3657-3660 (Pubitemid 44000247)
35. Ramachandran R, Hollenberg M (2008) Proteinases and signalling: Pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 153(Suppl 1):S263-S282 (Pubitemid 351340983)
36. Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD (2012) Targeting proteinase-activated receptors: Therapeutic potential and challenges. Nat Rev Drug Discov 11:69-86
37. Rattenholl A, Seeliger S, Buddenkotte J, Schon M, Schon M, Stander S, Vergnolle N, Steinhoff M (2007) Proteinase-activated receptor-2 (PAR2): A tumor suppressor in skin carcinogenesis. J Invest Dermatol 127:2245-2252 (Pubitemid 47258489)
38. Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW, Baba HA (2007) AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol 13:6470-6477
39. Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: A smallmolecule inhibitor of STAT3 activation and dimerization. Chem Biol 13:1235-1242 (Pubitemid 44750735)
40. Sevigny LM, Zhang P, Bohm A, Lazarides K, Perides G, Covic L, Kuliopulos A (2011) Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci USA 108(20):8491-8496
41. Shi X, Gangadharan B, Brass L, Ruf W, Mueller B (2004) Proteaseactivated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2:395-402 (Pubitemid 39031073)
42. Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y, Yamada N, Nishihara T, Ohira M, Hirakawa K (2004) A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol 24:1401-1406
43. Socoteanu MP, Mott F, Alpini G, Frankel AE (2008) c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol 14:2990-2994
44. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger T, Hollenberg M (2005) Proteinaseactivated receptors: Transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26:1-43 (Pubitemid 40209385)
45. Svitkina T, Bulanova E, Chaga O, Vignjevic D, Kojima S, Vasiliev J, Borisy G (2003) Mechanism of filopodia initiation by reorganization of a dendritic network. J Cell Biol 160(3):409-421 (Pubitemid 36182731)
46. Terada T, Okada Y, Nakanuma Y (1996) Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 23:1341-1344 (Pubitemid 26181214)
47. Varnholt H, Asayama Y, Aishima S, Taguchi K, Sugimachi K, Tsuneyoshi M (2002) C-met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma. Oncol Rep 9:35-41
48. Versteeg H, Schaffner F, Kerver M, Petersen H, Ahamed J, Felding-Habermann B, Takada Y, Mueller B, Ruf W (2008) Inhibition of tissue factor signaling suppresses tumorgrowth. Blood 111:190-199
49. Welzel T, McGlynn K, Hsing A, O'Brien T, Pfeiffer R (2006) Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra-and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 98(12):873-875 (Pubitemid 43923444)